Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

$100M stock pop as TH-302 approaches Threshold of success in pancreatic cancer

This article was originally published in Scrip

Executive Summary

Threshold Pharmaceutical's hypoxia-targeted drug candidate TH-302 has produced a significant 63% extension in progression-free survival in a Phase IIb study in pancreatic cancer, top-line data show. The drug was the subject of a licensing deal worth up to $525 million with Merck KGaA earlier this month (scripintelligence.com, 3 February 2012), and the share price of Threshold jumped by $2.95 to $6.45 (84%) on the news, before drifting to $5.14 by the end of 21 February 2012. The market thus valued the news of clinical success at around $100 million.

You may also be interested in...



Aptinyx To Forge Ahead With Pivotal PTSD Study

Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.

Approval Beckons For Orchard’s Gene Therapy Libmeldy

Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.

Kite’s Tecartus PRIMEd For EU Market With CHMP Nod

Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.

Topics

Related Companies

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel